US-based Atomwise has formed four new alliances to leverage its artificial intelligence (AI)...
- Gene therapy biotech Genenta raises €13.2m in funding round
- Draper Q&A: upgrading CAR-T therapy manufacturing
- AZ licenses PARPi to Theragnostics to develop novel radiopharmaceuticals
- Can Pharmaoffer become the Amazon of pharma raw materials?
- Medidata CEO Tarek Sherif on the past and future of pharma R&D
Join NSF’s Robyn Meurant and Rachel Carmichael at MMPathIC Event on 23 September
The Manchester Molecular Pathology Innovation Centre (MMPathIC), in collaboration with the Diagnostics and Technology Accelerator (DiTA) and NIHR Manchester Biomedical Research Center, is hosting a workshop on the 23 September at the Manchester Science Partnership Citylabs.
The Antibody Dependent Cell Mediated Cytotoxicity
The medical indications of therapeutic antibodies (tAb) have been growing. The antibody dependent cell-mediated cytotoxicity (ADCC) is a mechanism of immune defence attributed to the mode of action of several tAb, in particular, tumour cell targeting.
Atomwise inks four new deals for AI-based drug discovery
US-based Atomwise has formed four new alliances to leverage its artificial intelligence (AI) technology for the discovery of new drugs across various therapeutic areas.
Gene therapy biotech Genenta raises €13.2m in funding round
Milan-based clinical stage biotech Genenta Science has announced it has raised €13.2m at the closing of its third funding round, bringing its total financial backing to €30.2m since it was founded in 2014.
Draper Q&A: upgrading CAR-T therapy manufacturing
Draper is seeking to update the manufacturing processes and technology used for CAR-T cancer therapies to improve the efficiency and access. The company’s head of precision medicine and cell bioprocessing Jenna Balestrini explains the issues with the current viral vector approach and how Draper’s four modules, and particularly the microfluidics electroporation system, can transform the CAR-T cell therapy space.
Medicinal Product Information for Parenterals under the New Law
For medicinal products used solely by medical personnel, the Information for Professionals can now be within the packaging instead of the Patient Information, with the approval of Swissmedic.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.